The largest database of trusted experimental protocols

234 protocols using interleukin 7 (il 7)

1

Quantification of T-cell Responses

Check if the same lab product or an alternative is used in the 5 most similar protocols
Every 3 weeks, 45 mL peripheral blood was drawn into EDTA tubes and peripheral blood mononuclear cells (PBMC) were isolated using Ficoll gradient centrifugation for each subject. PBMCs were thawed in RPMI1640 with 10% FBS and incubated for 7 days at 37°C, 5% CO2. On day 1 and 4, the medium was refreshed and supplemented with 5 ng/mL IL7 or 5 ng/mL IL7 and 4 ng/mL IL2 (R&D Systems), respectively. After 7 days, PBMCs were harvested and rested for 16 hours, then seeded in 2 or 3 replicates (depending on sample availability) on IFNγ/Granzyme-B/TNFα FluoroSpot plates (Mabtech) at 100,000 to 150,000 cells/well in RPMI-10% FBS. Cells were incubated either with the RPMI-10% FBS medium, or the peptides (5 μg/mL), or peptide pools (5 μg/mL per peptide) overnight at 37°C, 5% CO2. Development was performed according to the manufacturer's instructions. Results were acquired with a Mabtech IRIS reader and analyzed using the Mabtech Apex software. In vitro stimulated (IVS) ELISpot results were considered positive when after subtracting the corresponding nonstimulated control (ΔSFU), the result was >2.5-fold higher than the DMSO negative control. A response was considered “boosted” compared with pre-vaccination when at least two-fold increase in ΔSFU was achieved.
+ Open protocol
+ Expand
2

Accelerated Dendritic Cell Priming for HLA-A2-EV10

Check if the same lab product or an alternative is used in the 5 most similar protocols
Naive precursors specific for HLA-A2-EV10 were primed in vitro using an accelerated dendritic cell (DC) coculture protocol as described previously [9, 14, 15] . Briefly, thawed PBMCs were resuspended at 5 × 10 6 cells/well in AIM-V medium (Thermo Fisher Scientific) supplemented with Flt3 ligand (Flt3L; 50 ng/ml; R&D Systems) in the absence or presence of rosiglitazone ( 40μM; Sigma-Aldrich) or IL-7 (20 ng/mL; R&D Systems). After 24 hr (day 1), the Melan-A peptide EV20 (1 µM) was added to the cultures, and DC maturation was induced using a standard cocktail of inflammatory cytokines, incorporating IL-1β (10 ng/mL), IL-7 (0.5 ng/mL), prostaglandin E2 (PGE2; 1 μM), and TNF (1,000 U/mL) (all from R&D Systems), or ssRNA40 (TLR8L; 0.5 μg/mL; InvivoGen). The cultures were supplemented on day 2 with FCS (10% v/v; Sigma-Aldrich). Medium was replaced every 3 days thereafter with fresh R+ containing FCS (10% v/v; Sigma-Aldrich). Antigen-specific CD8 + T cells were characterized via flow cytometry on day 10.
+ Open protocol
+ Expand
3

Hematopoietic Progenitor Cell Differentiation

Check if the same lab product or an alternative is used in the 5 most similar protocols
The differentiation experiments were performed as described previously,30 (link) plating 1 x 104 LincKit+ hematopoietic progenitor cells per 24-well plates of OP9-DL1 feeders in OP9 culture medium supplemented with 5 ng/mL Flt3 ligand (R&D Systems) and 5 ng/mL IL7 (or 1-0.2 ng/mL IL7 where indicated) (R&D Systems or Peprotech).
OP9-DL1 bone marrow stromal cells30 (link) were maintained in MEMalpha medium (Gibco), supplemented with 20% fetal bovine serum (FCS; Hyclone), penicillin (100 U/mL)-streptomycin (100 μg/mL), 2 mM L-glutamine (Gibco) and incubated at 37°C with 7% CO2 and 95% humidity. E13.5 fetal liver cells were stained with biotin-conjugated lineage cocktail antibodies [Gr-1 (Ly-6G & 6C), Ter119 (Ly-76), CD3ε, and B220 (CD45R); eBioscience], PE-conjugated streptavidin (BD Biosciences, 1:200) and CD117-APC (cKit, Immunosource, 1:200). LincKit+ cells were sorted using a FACSAria II machine (BD Biosciences) and FACSDiva software. Dead cells were discarded via DAPI stain.
+ Open protocol
+ Expand
4

Intracellular Signaling by Flow Cytometry

Check if the same lab product or an alternative is used in the 5 most similar protocols
Intracellular signaling was assessed by determining the phosphorylation of STAT5 by flow cytometry. In brief, 500 μL of PBMC suspension (106 cells/μL) was incubated for 15 minutes at 37 °C with 4000 U/mL IL-2 (kindly provided by N. Ødum, Copenhagen University, Copenhagen) or 10 ng/mL IL-7 (Peprotech, Stockholm, Sweden). Furthermore, PBMC from a total of ten participants (five ‘CC’ and five ‘TT’) were stimulated with 10 ng/mL IL-7 in combination with sIL-7RA (IL-7 + sIL-7RA) in three different ratios: 1 to 100, 1 to 1000, or 1 to 2000 (sIL-7RA was purchased from R&D Systems, Abingdon, UK). The stimulated PBMC were fixated with fixation buffer (BD), incubated with monoclonal antibodies (CD3-FITC and CD4-APC-H7) (BD), permeabilized with permeabilization buffer (BD), incubated for 30 min with antibody pSTAT5-AF647 (BD), and immediately assessed by flow cytometry (representative plots in Fig. 2A–C).
+ Open protocol
+ Expand
5

Leukemia Cell Viability Assay

Check if the same lab product or an alternative is used in the 5 most similar protocols
Leukemia cell viability was determined using the CellTiter-Glo® ATP assay (Promega; Madison, WI), according to the manufacturer’s instructions. For experiments with E3330, leukemia cells were cultured with RPMI supplemented with 5% FBS (RPMI-5). TAIL7 cells were cultured with IL-7 (10ng/ml), and TALL-104 cells with IL-2 (20ng/mL; R&D Systems). Primary T-ALL cells were cultured with IL-7 plus IL-9 (10ng/ml; R&D Systems), and leukemia cells from the ICN-induced T-ALL model were cultured with IL-7 (10ng/mL), SCF (10ng/mL; R&D Systems) and FLT3L (10ng/mL; R&D Systems). All cultures were performed in triplicates, for the timepoints indicated. Plates were analyzed in a SpectraMax Gemini EM microplate reader (Molecular Devices; Sunnyvale, CA).
+ Open protocol
+ Expand
6

PBMC and DC-based T cell expansion

Check if the same lab product or an alternative is used in the 5 most similar protocols
PBMC method: PBMC (2–4×106) were pulsed with EBNA1 and BZLF1 or BARF1 pepmixes (0.5–2 μg/ml), and cultured in TCM supplemented with IL4 (1,000 U/ml) and IL7 (10 ng/ml) for 8 to 10 days before analysis. During this culture period, T cells expanded 2- to 3-fold. DC method: CD14-negative PBMCs (10–20×106) were used as responder cells and stimulated with pepmix- or individual pulsed (25 μg/ml) DCs at a stimulator:responder (S:R) ratio of 1:10. Cells were cultured in TCM supplemented with IL7 (10 ng/ml), IL12 (10 ng/ml), IL15 (5 ng/ml) and IL6 (100 ng/ml) (R&D Systems).[25 (link)] On day 10, T cells were harvested and restimulated with pepmix-pulsed DCs at a S:R ratio of 1:10 in the presence of IL7 (10 ng/ml). Cells were cultured in TCM for another 7 days fed with IL2 (50 U/ml, Biological Resources Branch, National Cancer Institute, Frederick, MD) or IL15 (5 ng/ml) twice weekly from day 14. During this culture period, cells expanded 5- to 10-fold. On day 17 after initial stimulation, cells were harvested, counted and analyzed for their specificity and functional capacity. To further expand the cells, T cells were restimulated weekly at a S:R ratio of 1:10 with pepmix-pulsed DCs in TCM, supplemented with IL2 (50 U/ml) or IL15 (5 ng/ml) twice weekly.
+ Open protocol
+ Expand
7

Murine and Human Cytokine Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols
Recombinant murine (rm) SCF, IL-1α, IL-3, IL-7, IL-15, FLT3-L, G-CSF, M-CSF, and GM-CSF and recombinant human (rh) SCF, IL-7, IL-15, FLT3-L, GM-CSF and TNFα were purchased from R&D Systems.
+ Open protocol
+ Expand
8

Activation and Survival of Naive CD4+ T Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols
Sorted naive CD4+ T cells were used for in vitro cultures in Click’s medium supplemented with β-mercaptoethanol, 10% fetal bovine serum, and 1% penicillin-streptomycin. For T cell activation, naive T cells were activated with plate-bound 5 µg/ml anti-CD3 (2C11) and 5 µg/ml anti-CD28 (37.51) in the presence of 100 U/ml IL-2 (R&D Systems) for 18 h and analyzed by flow cytometry for activation and apoptotic markers. For T cell survival in response to IL-7, naive T cells were cultured with or without 2 ng/ml IL-7 (R&D Systems) for 3 d and analyzed by flow cytometry.
+ Open protocol
+ Expand
9

Priming Naive HLA-A2–EV10 Specific T Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols
Naive precursors specific for HLA-A2–EV10 were primed in vitro using an accelerated dendritic cell (DC) coculture protocol as described previously (11 (link), 16 (link), 17 ). Briefly, thawed PBMCs were resuspended at 5 × 106 cells/well in AIM-V medium (Thermo Fisher Scientific) supplemented with Flt3 ligand (Flt3L; 50 ng/mL; R&D Systems) in the absence or presence of rosiglitazone (40 μM; Sigma-Aldrich) or IL-7 (20 ng/mL; R&D Systems). After 24 hr (day 1), the Melan-A peptide EV20 (1 μM) was added to the cultures, and DC maturation was induced using a standard cocktail of inflammatory cytokines, incorporating IL-1β (10 ng/mL), IL-7 (0.5 ng/mL), PGE2 (1 μM), and TNF (1,000 U/mL) (all from R&D Systems), or ssRNA40 (TLR8L; 0.5 μg/mL; InvivoGen). The cultures were supplemented on day 2 with FCS (10% v/v; Sigma-Aldrich). Medium was replaced every 3 days thereafter with fresh R+ containing FCS (10% v/v; Sigma-Aldrich). Antigen-specific CD8+ T cells were characterized via flow cytometry on day 10.
+ Open protocol
+ Expand
10

Priming Naive HLA-A2–EV10 Specific T Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols
Naive precursors specific for HLA-A2–EV10 were primed in vitro using an accelerated dendritic cell (DC) coculture protocol as described previously (11 (link), 16 (link), 17 ). Briefly, thawed PBMCs were resuspended at 5 × 106 cells/well in AIM-V medium (Thermo Fisher Scientific) supplemented with Flt3 ligand (Flt3L; 50 ng/mL; R&D Systems) in the absence or presence of rosiglitazone (40 μM; Sigma-Aldrich) or IL-7 (20 ng/mL; R&D Systems). After 24 hr (day 1), the Melan-A peptide EV20 (1 μM) was added to the cultures, and DC maturation was induced using a standard cocktail of inflammatory cytokines, incorporating IL-1β (10 ng/mL), IL-7 (0.5 ng/mL), PGE2 (1 μM), and TNF (1,000 U/mL) (all from R&D Systems), or ssRNA40 (TLR8L; 0.5 μg/mL; InvivoGen). The cultures were supplemented on day 2 with FCS (10% v/v; Sigma-Aldrich). Medium was replaced every 3 days thereafter with fresh R+ containing FCS (10% v/v; Sigma-Aldrich). Antigen-specific CD8+ T cells were characterized via flow cytometry on day 10.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!